Details related to the preventive effect of the novel coronavirus infection (Corona 19) vaccine of Sinobac, a Chinese pharmaceutical company, which has undergone clinical trials in Brazil, is expected to be released early next year.
According to Brazilian media on the 26th (local time), the government of Sao Paulo said that the announcement of the preventive effect of coronavirus will be made by January 7th next year.
The announcement of the coronavirus prevention effect was initially scheduled to be made on the 15th, was delayed to the 23rd, and then again postponed to the beginning of next year.
The government of Sao Paulo said that the reason for the delay in the announcement was that the preventive effect was different in each country that conducted the coronavirus clinical trial.
Turkish health authorities announced on the 24th that the prevention effect of coronavirus was 91.25%.
The Butantang Research Center under the government of Sao Paulo, which has been conducting a phase 3 clinical trial of coronavirus with Synovac, only revealed on the 23rd that the preventive effect of coronavirus exceeded 50%, which was sufficient to obtain approval for emergency use, and did not disclose specific figures.
Proposal Go Lynchtain, head of the São Paulo State Health Department, said that the prevention effect of coronavirus did not reach 90%, but it was at a level that could reduce the impact of Corona 19 on the public.
Apart from the delay in the announcement of the preventive effect of coronavirus, the state government of Sao Paulo is planning to start vaccination from January 25 next year if the approval of the health authorities is granted.
(Yonhap News/Photo = Yonhap News)